Subscribe To

Price Alert Latest News Economic Calendar News

RVVTF / Revive Therapeutics to review next steps for Phase 3 Bucillamine study in COVID-19 patients

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has said it will review the next steps for the Phase 3 clinical trial of Bucillamine, its oral anti-inflammatory and antiviral drug, in patients with mild to moderate COVID-19. Following its Type C meeting with the US Food and Drug Administration (FDA) and with new hospitalizations of COVID-19 patients now falling, the life sciences company said it has evaluated its strategies for patient recruitment and has opted for a review of the study's post-dose selection data of 500 subjects for efficacy. Read More

Demo Live Account See Partner Details

Content Topics

Revive

Therapeutics

Review

Steps

Phase

Bucillamine

Covid 19

Patients

Stock

RVVTF

Posted: Apr 19 2023, 08:11

Author Name: Proactive Investors

RVVTF News

By Proactive Investors
July 28, 2023

Revive Therapeutics files patent application to treat chemical warfare agents exposure

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF). said it has filed a provisional patent application for the use of Bucillamine as a potential treatment

By Proactive Investors
July 6, 2023

Revive Therapeutics' study on safety and efficacy of Bucillamine to treat COVID 19 shows no statistical significance

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said the results of its Phase 3 clinical trial evaluating the safety and efficacy of oral Bucillamine i

By Reuters
July 6, 2023

Revive Therapeutics' experimental COVID treatment fails in late-stage study

Canada-based Revive Therapeutics said on Thursday its experimental COVID-19 treatment did not meet the main goal of a late-stage study.

By Proactive Investors
May 30, 2023

Revive Therapeutics staying the course on Phase 3 trial of Bucillamine in Covid-19 patients after meeting with FDA

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has issued an update on the Phase 3 trial of its drug Bucillamine in patients with mild to moderate COV

By Proactive Investors
May 12, 2023

Small cap snapshot: Phunware, Willow Biosciences, Jushi Holdings, East Side Games, Revive Therapeutics

By Proactive Investors
May 12, 2023

Revive Therapeutics halts Bucillamine for COVID-19 study; seeks data evaluation to inform next steps

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said its Phase 3 clinical trial evaluating Bucillamine, an oral drug with anti-inflammatory and antivi

By Proactive Investors
May 2, 2023

Revive Therapeutics says date set for independent Data and Safety Monitoring Board meeting for its Bucillamine Phase 3 clinical trial

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has revealed that the independent Data and Safety Monitoring Board (DSMB) meeting for its Bucillamine P

By Proactive Investors
April 19, 2023

Revive Therapeutics to review next steps for Phase 3 Bucillamine study in COVID-19 patients

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has said it will review the next steps for the Phase 3 clinical trial of Bucillamine, its oral anti-inf

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.